Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - phenol, quantity: 250 mg - injection, solution - excipient ingredients: almond oil - haemorol is indicated for the treatment of symptomatic haemorrhoids in patients with an inadequate response to conservative therapy such as dietary manipulation. it must only be injected submucosally and its use is usually confined to first degree or second degree haemorrhoids.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - paraldehyde, quantity: 5 ml - injection, solution - excipient ingredients: hydroquinone - paraldehyde has been used as a sedative and hypnotic in a variety of clinical situations, although it has been largely replaced by safer and/or more effective agents. it may also be used in the treatment of convulsive episodes arising from tetanus, status epilepticus and poisoning by convulsive drugs, when other agents are inappropriate or ineffective. paraldehyde may be effective in reducing the anxiety associated with withdrawal from drugs such as narcotics or barbiturates, as well as in the management of acute agitation or delirium tremens due to alcohol withdrawal. paraldehyde is only recommended for use in these conditions when other treatments are ineffective or deemed inappropriate.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - caffeine, quantity: 12.5 mg - oral liquid, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injections - cafnea oral solution is indicated for the short-term treatment of apnoea of prematurity in infants between 28 and 33 weeks gestational age.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - caffeine, quantity: 20 mg - injection, intravenous infusion - excipient ingredients: sodium citrate dihydrate; water for injections; citric acid monohydrate - cafnea injection is indicated for the short-term treatment of apnoea of prematurity in infants between 28 and 33 weeks gestational age.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - arsenic trioxide, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression. for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl), in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - tobramycin sulfate, quantity: 762.24 mg (equivalent: tobramycin, qty 500 mg) - injection, concentrated - excipient ingredients: sulfuric acid; water for injections; sodium hydroxide - tobra-day is indicated for once daily intravenous use in the treatment of cystic fibrosis patients (greater than 5 years old) with acute pulmonary exacerbations caused by susceptible organisms.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - fluorescein sodium, quantity: 100 mg/ml - injection - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - diagnostic: intravenous injection of sodium fluorescein dye followed by multiframe photography (angiography) or opthalmoscopic evaluation (angioscopy). used in evaluation of wide range of retinal and choroidal diseases. less commonly used to evaluate abnormalities of the optic nerve and iris. may be used in the diagnosis and management of macular and vascular (including diabetic) diseases.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - naproxen, quantity: 25 mg/ml - oral liquid, suspension - excipient ingredients: sorbitol solution (70 per cent) (crystallising); aluminium magnesium silicate; purified water; sucrose; sodium chloride; fumaric acid; methyl hydroxybenzoate; sunset yellow fcf; sodium hydroxide; flavour - treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, for the symptomatic treatment of primary dysmenorrhoea, for the relief of acute and/or chronic pain states in which there is an inflammatory component and as an analgesic in acute migraine attack.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - acetylcysteine, quantity: 6 g - injection - excipient ingredients: sodium hydroxide; water for injections - as an antidote for paracetamol poisoning: acetadote injection is indicated in the treatment of paracetamol overdose to protect against hepatoxicity.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - hydrochlorothiazide, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; calcium hydrogen phosphate dihydrate; sunset yellow fcf aluminium lake - hypertension: may be used alone or in combination with other antihypertensive drugs. oedema: associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure (see precautions), premenstrual tension, and drug induced oedema.